Constellation Pharmaceuticals (CNST) Sets New 52-Week Low at $5.57

Share on StockTwits

Constellation Pharmaceuticals Inc (NASDAQ:CNST)’s share price reached a new 52-week low during trading on Wednesday . The company traded as low as $5.57 and last traded at $5.83, with a volume of 295 shares. The stock had previously closed at $5.91.

CNST has been the topic of a number of recent research reports. Cann initiated coverage on Constellation Pharmaceuticals in a research note on Monday, August 13th. They set an “outperform” rating and a $21.00 price objective on the stock. Zacks Investment Research upgraded Constellation Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.75 price objective on the stock in a research note on Monday, October 15th. JPMorgan Chase & Co. initiated coverage on Constellation Pharmaceuticals in a research note on Monday, August 13th. They set an “overweight” rating and a $17.00 price objective on the stock. Oppenheimer initiated coverage on Constellation Pharmaceuticals in a research note on Monday, August 13th. They set an “outperform” rating and a $21.00 price objective on the stock. Finally, BMO Capital Markets initiated coverage on Constellation Pharmaceuticals in a research note on Monday, August 13th. They set an “outperform” rating and a $19.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $17.15.

Constellation Pharmaceuticals (NASDAQ:CNST) last posted its quarterly earnings data on Tuesday, August 14th. The company reported ($9.96) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.71) by ($9.25). On average, equities research analysts predict that Constellation Pharmaceuticals Inc will post -2.88 EPS for the current fiscal year.

An institutional investor recently bought a new position in Constellation Pharmaceuticals stock. TRV GP LLC purchased a new stake in Constellation Pharmaceuticals Inc (NASDAQ:CNST) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 3,034,083 shares of the company’s stock, valued at approximately $20,419,000. Constellation Pharmaceuticals comprises approximately 17.0% of TRV GP LLC’s investment portfolio, making the stock its 2nd largest holding. TRV GP LLC owned approximately 11.80% of Constellation Pharmaceuticals as of its most recent SEC filing. Hedge funds and other institutional investors own 0.01% of the company’s stock.

Constellation Pharmaceuticals Company Profile (NASDAQ:CNST)

Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidate CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors, as well as for the treatment of solid tumors in combination with immune checkpoint inhibitors.

Further Reading: What is the 52-week high/low?

Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply